BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare BioCryst Pharmaceuticals to similar companies based on the strength of its analyst recommendations, risk, valuation, earnings, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 50.0% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BioCryst Pharmaceuticals has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 8.27, suggesting that their average share price is 727% more volatile than the S&P 500.
This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioCryst Pharmaceuticals Competitors||-5,993.97%||-219.09%||-39.48%|
Earnings and Valuation
This table compares BioCryst Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||-$55.14 million||-7.81|
|BioCryst Pharmaceuticals Competitors||$284.49 million||$33.78 million||76.11|
BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and recommmendations for BioCryst Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioCryst Pharmaceuticals Competitors||866||3223||11693||232||2.71|
BioCryst Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 93.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.26%. Given BioCryst Pharmaceuticals’ higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than its peers.
BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 7 of the 12 factors compared.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
What are top analysts saying about BioCryst Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals and related companies.